Accuray Inc (ARAY) Files 10-K for the Fiscal Year Ended on June 30, 2018

GuruFocus.com
0
In this article:

- By insider

Accuray Inc (ARAY) files its latest 10-K with SEC for the fiscal year ended on June 30, 2018. Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise treatment solutions. Its products includes the CyberKnife Systems and the TomoTherapy Systems. Accuray Inc has a market cap of $338.270 million; its shares were traded at around $3.95 with and P/S ratio of 0.83.


For the last quarter Accuray Inc reported a revenue of $113.8 million, compared with the revenue of $112.1 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $404.9 million, an increase of 5.6% from last year. For the last five years Accuray Inc had an average revenue growth rate of 4.1% a year.

The reported loss per diluted share was 28 cents for the year, compared with the loss per share of $0.47 in the previous year. The Accuray Inc had an operating margin of -0.94%, compared with the operating margin of -2.56% a year before. The 10-year historical median operating margin of Accuray Inc is -3.74%. The profitability rank of the company is 3 (out of 10).

At the end of the fiscal year, Accuray Inc has the cash and cash equivalents of $83.1 million, compared with $72.1 million in the previous year. The long term debt was $131.1 million, compared with $51.5 million in the previous year. Accuray Inc has a financial strength rank of 4 (out of 10).

At the current stock price of $3.95, Accuray Inc is traded at 41% discount to its historical median P/S valuation band of $6.70. The P/S ratio of the stock is 0.83, while the historical median P/S ratio is 1.40. The stock lost 2.44% during the past 12 months.

For the complete 20-year historical financial data of ARAY, click here.

This article first appeared on GuruFocus.


Advertisement

Recommended Stories